SS-31 Research Timeline: From Discovery to FDA Approval (2001–2026)

Research laboratory — SS-31 research timeline overview

The SS-31 research timeline is one of the longest-running stories in mitochondrial medicine: more than two decades from the peptide’s identification in a mitochondria-targeted peptide series to the first FDA approval of a mitochondria-targeted therapy in September 2025. This SS-31 research timeline walks through the key milestones — the discovery program, the cardiolipin mechanism work, the long clinical road with its failures and near-misses, and the landmark approval — strictly as a research and regulatory history. No medical advice, no efficacy promises for any unapproved use, and no dosing or administration information appears here.

Research-use-only disclaimer: SS-31 (elamipretide) is a prescription-only medicine approved by the FDA in September 2025 solely for Barth syndrome; every other use remains experimental. This article is an educational research overview of the SS-31 research timeline. It contains no medical advice, no dosage information, no usage instructions, and nothing suggesting any human use. All products on this site are sold strictly for laboratory research use.

2001–2004: The Szeto-Schiller Peptide Program

The SS-31 research timeline begins with a design problem: how to get a therapeutic molecule into mitochondria, the organelles where most drug candidates never reach. In the early 2000s, the Szeto-Schiller research program — led by Hazel Szeto and Peter Schiller — developed a series of small aromatic-cationic peptides that concentrated in mitochondria hundreds of times more than in the cytosol. These “SS peptides” were designed to scavenge reactive oxygen species at their source, inside the inner mitochondrial membrane.

SS-31 emerged from this series as one of the lead candidates. Unlike earlier mitochondria-targeted antioxidants, it accumulated in mitochondria without relying on the mitochondrial membrane potential — a practical advantage, because membrane potential collapses precisely when cells are under stress. Early published work reported that SS-31 reduced intracellular oxidative stress and protected cells from death induced by mitochondrial injury. The compound entered development through Stealth BioTherapeutics (originally Stealth Peptides), under the early development names Bendavia and MTP-131 — a naming evolution that tracks the early SS-31 research timeline.

2005–2013: Mechanism Work — The Cardiolipin Connection

A pivotal chapter in the SS-31 research timeline was pinning down how the peptide actually works. Through the late 2000s and early 2010s, published studies converged on cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane, where it organizes the electron transport chain into efficient supercomplexes.

The key 2014 paper by Birk, Chao, and colleagues (British Journal of Pharmacology) reported that SS-31 binds cardiolipin selectively, protecting it from oxidative damage and promoting electron transport and ATP synthesis. A companion paper by Szeto (2014, same journal) framed SS-31 as a first-in-class “cardiolipin-protective compound” — the mechanistic anchor of the SS-31 research timeline. When cardiolipin is damaged — as happens with age and in mitochondrial disease — the electron transport chain disorganizes, energy output falls, and reactive oxygen species rise. SS-31’s proposed mechanism is to stabilize that lipid and the machinery it holds together. The proposed mechanism is reviewed in detail in our companion article on SS-31 mechanism of action research — and summarized for reference in Elamipretide on Wikipedia.

Why the mechanism mattered. A compound can show promising effects in cells for many reasons. The cardiolipin work gave SS-31 something rarer: a defined molecular target (cardiolipin), a measurable biochemical readout (cardiolipin oxidation and organization), and a testable hypothesis for which diseases it might help. That target-based rationale is what carried the SS-31 research timeline into human trials.

2010s: The Clinical Program Expands — and Stumbles

The 2010s are the busiest and most instructive decade of the SS-31 research timeline. Under the names Bendavia, MTP-131, and finally elamipretide, the compound was tested across cardiology, ophthalmology, nephrology, and rare mitochondrial disease. The record is a mixture of signals and failures — and the failures are as informative as the signals.

Glass test tubes in a lab — SS-31 research timeline clinical era
Photo: Pexels
~2010s

EMBRACE-STEMI. A Phase 2a trial in patients undergoing intervention for first-time anterior heart attack tested elamipretide’s cardioprotective potential. The trial did not reduce myocardial infarct size, its primary goal — though investigators noted a reduced incidence of chronic heart failure, which warranted further cardiac investigation.

~2010s

PROGRESS-HF. A randomized, double-blind, placebo-controlled Phase 2 trial in stable heart failure with reduced ejection fraction. The primary endpoint (left ventricular end-systolic volume reduction) was not met, though mitochondrial function and quality-of-life measures showed improvements.

2010s–2023

MMPOWER program. Trials in primary mitochondrial myopathy: early small studies showed near-miss signals, but the larger MMPOWER-3 Phase 3 trial failed on its walk-test endpoint. This remains the clearest example on the SS-31 research timeline of a promising mechanism not translating into a large-trial win.

2010s–2020s

ReCLAIM program. Randomized, double-blind, placebo-controlled Phase 2 trials in dry age-related macular degeneration. Primary endpoints (visual acuity, geographic atrophy area) were not met — but secondary retinal measures, including ellipsoid zone attenuation in the mitochondria-rich photoreceptor layer, showed notable signals that redirected the ophthalmology program.

2017–2024

TAZPOWER. The Barth syndrome program — and the trial that ultimately changed the SS-31 research timeline. TAZPOWER (SPIBA-201) was a randomized, double-blind, placebo-controlled crossover Phase 2 trial followed by a long open-label extension. The randomized phase did not beat placebo on its primary endpoints (6-minute walk test, fatigue score), but the extension phase showed sustained improvements in knee extensor muscle strength, walk distance, fatigue scores, and cardiac parameters over up to 168 weeks — published in Genetics in Medicine in 2024.

Notice the pattern that defines the SS-31 research timeline: short randomized phases often missed their primary endpoints, while longer treatment in the Barth syndrome extension showed accumulating benefits. Whether that reflects the biology of mitochondrial repair (slow, cumulative) or the statistics of small open-label extensions is exactly the debate the field has been having.

September 2025: The Landmark — First FDA Approval of a Mitochondria-Targeted Therapy

On September 19, 2025, the U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide hydrochloride), sponsored by Stealth BioTherapeutics — the first FDA-approved treatment for Barth syndrome, and, as the FDA noted, a first-in-class medication. The approval was based on improvement in knee extensor muscle strength, an intermediate clinical endpoint measured by handheld dynamometry in the TAZPOWER program, which the FDA considered reasonably likely to predict clinical benefit such as standing and walking more easily.

What “accelerated approval” means. Accelerated approval is granted based on an intermediate endpoint reasonably likely to predict clinical benefit, with a required post-approval confirmatory trial to verify that benefit. The FDA is requiring a randomized, double-blind, placebo-controlled trial to confirm that the muscle-strength changes translate into patient benefit. Continued approval may depend on that confirmation. This is the regulatory framework that now governs the latest chapter of the SS-31 research timeline.

Two facts about the approval deserve emphasis for anyone reading the SS-31 research timeline honestly. First, the approval is indication-specific: elamipretide is approved for improving muscle strength in Barth syndrome patients meeting the label criteria — not for heart failure, macular degeneration, aging, or any other condition, all of which remain investigational. Second, Barth syndrome itself is a cardiolipin disease: caused by mutations in the gene responsible for cardiolipin remodeling, so patients have abnormal cardiolipin from birth. A cardiolipin-binding drug for a cardiolipin-remodeling disease is the most mechanistically matched pairing in the entire SS-31 research timeline — which is plausibly why this indication succeeded where broader ones did not.

Multichannel pipette in research — SS-31 research timeline laboratory work
Photo: Pexels

SS-31 Research Timeline: Trial Results at a Glance

Trial programIndication studiedWhat the published results show
EMBRACE-STEMIAcute heart attack (anterior STEMI)Did not reduce infarct size; reduced incidence of chronic heart failure noted
PROGRESS-HFHeart failure with reduced ejection fractionPrimary endpoint not met; mitochondrial function and quality-of-life signals
MMPOWER-3Primary mitochondrial myopathyFailed on primary walk-test endpoint
ReCLAIM (1 & 2)Dry age-related macular degenerationPrimaries not met; secondary retinal (ellipsoid zone) signals
TAZPOWER + extensionBarth syndromeRandomized phase missed primaries; extension showed sustained strength, walk, fatigue, and cardiac improvements — basis of 2025 approval

This table is the heart of the SS-31 research timeline for readers who want the unvarnished version: four programs with missed primary endpoints alongside real secondary signals, and one ultra-rare disease program that converted long-term signals into an approval. Both halves are the truth.

2026 and Beyond: What the SS-31 Research Timeline Points To Next

As of 2026, the SS-31 research timeline has three live threads, and each continues the SS-31 research timeline in a different direction. First, the required confirmatory trial in Barth syndrome, which will determine whether accelerated approval converts to full approval. Second, the ophthalmology program, where the ellipsoid-zone endpoint from ReCLAIM-2 became the basis for a redesigned Phase 3 effort in dry AMD. Third, the broader mechanistic literature — 2025 reviews in Biomedicine & Pharmacotherapy and the International Journal of Molecular Sciences continue to map elamipretide’s mitochondrial mechanism and therapeutic potential across heart failure, kidney injury, and neurodegeneration models, all still investigational.

What the timeline does not support is any claim that SS-31 is a validated therapy for aging, athletic performance, or general “mitochondrial optimization” in humans. Those ideas circulate online; the SS-31 research timeline as published contains no such evidence. The honest reading is narrower and more interesting: a cardiolipin-targeted peptide with a defined mechanism, a long record of mixed clinical results, and one landmark approval in the disease most mechanistically matched to it.

Related research on this site. For the mechanistic detail behind the milestones above, see our research overview of SS-31 mechanism of action and the pharmacokinetic picture in SS-31 half-life research. Readers interested in cognitive research peptides can compare Selank vs Semax, with research overviews of Semax nasal spray and Selank nasal spray. All compounds here are handled strictly as research materials — see our Semax 10mg and Selank 10mg research listings.

Researcher using pipettes — SS-31 research timeline ongoing studies
Photo: Wikimedia Commons

Key Takeaways: SS-31 Research Timeline

  • The SS-31 research timeline spans 2001–2026: from the Szeto-Schiller mitochondrial peptide program to the first FDA approval of a mitochondria-targeted therapy.
  • The mechanism chapter (cardiolipin binding, electron transport stabilization) gave the program a defined molecular target — summarized in Elamipretide on Wikipedia.
  • The clinical chapter is mixed: missed primary endpoints in heart attack, heart failure, mitochondrial myopathy, and dry AMD programs, alongside real secondary signals.
  • TAZPOWER’s long Barth syndrome extension converted sustained strength and function improvements into FDA accelerated approval of Forzinity on September 19, 2025.
  • The approval is indication-specific to Barth syndrome; every other use of elamipretide/SS-31 remains investigational, and a confirmatory trial is required.

SS-31 Research Timeline: Frequently Asked Questions

Direct answers about the SS-31 research timeline, kept to published facts.

When was SS-31 discovered?

SS-31 emerged in the early 2000s from the Szeto-Schiller program developing mitochondria-targeted aromatic-cationic peptides. It was developed by Stealth BioTherapeutics under the names Bendavia and MTP-131 before being renamed elamipretide. The SS-31 research timeline therefore starts as a chemistry and targeting story, not a disease story.

Is SS-31 the same as elamipretide?

Yes. SS-31 is the research code name; elamipretide is the international nonproprietary name, and Forzinity is the brand name of the FDA-approved product. All three refer to the same synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2). Throughout the SS-31 research timeline, the name changed with the development stage.

When did the FDA approve elamipretide?

September 19, 2025. The FDA granted accelerated approval to Forzinity (elamipretide) as the first treatment for Barth syndrome, based on improved knee extensor muscle strength in the TAZPOWER trial program. The FDA considers it a first-in-class medication. This is the landmark event of the SS-31 research timeline.

What is elamipretide approved for?

Only Barth syndrome: improving muscle strength in patients meeting the label criteria. It is not approved for heart failure, macular degeneration, aging, or any other condition — those remain investigational. The approval’s indication-specific nature is a key fact in the SS-31 research timeline.

Why did so many SS-31 trials fail their primary endpoints?

The published record shows a recurring pattern: short randomized phases in heart attack (EMBRACE-STEMI), heart failure (PROGRESS-HF), mitochondrial myopathy (MMPOWER-3), and dry AMD (ReCLAIM) missed primary endpoints while often showing secondary signals. Proposed explanations include short treatment durations for a slow mitochondrial mechanism and endpoints that may not capture the drug’s effects. The Barth syndrome program succeeded over much longer treatment — a contrast the field continues to debate.

What happens next in the SS-31 research timeline?

The FDA requires a post-approval confirmatory trial in Barth syndrome to verify clinical benefit. The ophthalmology program continues with a redesigned Phase 3 in dry AMD based on the ellipsoid-zone endpoint. Mechanistic research continues across heart failure, kidney injury, and neurodegeneration models — all investigational. PubMed indexes the primary papers as they appear.

SS-31 Research Timeline: Final Notes

The SS-31 research timeline rewards honest reading. It is a story of a well-defined mechanism meeting the hard realities of clinical translation: a decade of missed primaries, genuine secondary signals, and finally a landmark approval in the one disease whose molecular defect — broken cardiolipin remodeling — matches the drug’s molecular target. That arc contains both a caution about how hard translation is and a genuine milestone: the first time a mitochondria-targeted therapy cleared the FDA. Kept in that frame, the timeline is one of the most instructive case studies in modern peptide drug development.

Leave a Comment

Cart0
Cart0

Research Verification Required

This website contains research compounds available exclusively for qualified researchers and laboratory professionals. By entering, you confirm: